These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7483643)

  • 1. Atherosclerotic lesions in humans--plaque stabilization and regression.
    Kritz H; Sinzinger H
    Wien Klin Wochenschr; 1995; 107(18):555-66. PubMed ID: 7483643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of atherosclerosis: which components regress and what influences their reversal.
    Kramsch DM; Blankenhorn DH
    Wien Klin Wochenschr; 1992; 104(1):2-9. PubMed ID: 1546480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical investigations of the arrest and reversal of coronary artery disease.
    Farmer JA; Gotto AM
    Coron Artery Dis; 1995 Jun; 6(6):457-65. PubMed ID: 7551266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of lipid lowering measures on coronary perfusion].
    Steinmetz A; Maisch B; Noll B
    Z Kardiol; 1997; 86 Suppl 1():43-55. PubMed ID: 9173721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of the LDL-/HDL-cholesterol quotient on progression and regression of arteriosclerotic lesions. An analysis of controlled angiographic intervention studies].
    Gohlke H
    Wien Klin Wochenschr; 1992; 104(11):309-13. PubMed ID: 1621390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical morphology of human atherosclerotic lesions. Lessons from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth.
    Cornhill JF; Herderick EE; Vince DG
    Wien Klin Wochenschr; 1995; 107(18):540-3. PubMed ID: 7483640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Is regression of atherosclerosis possible?].
    Thomas D; Richard JL; Emmerich J; Bruckert E; Delahaye F
    Arch Mal Coeur Vaiss; 1992 Oct; 85 Spec No 3():47-57. PubMed ID: 1296545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heparin-induced extracorporeal LDL precipitation (HELP) in therapy refractory hypercholesterolemia and coronary heart disease: effect on clinical and morphological regression of coronary sclerosis].
    Schuff-Werner P
    Z Kardiol; 1997; 86 Suppl 1():57-64. PubMed ID: 9173722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shear stress-dependent platelet function after LDL cholesterol apheresis.
    Spieker LE; Ruschitzka F; Badimon JJ; Noll G; Corti R
    Thromb Res; 2004; 113(6):395-8. PubMed ID: 15226094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging.
    Corti R; Fuster V; Fayad ZA; Worthley SG; Helft G; Chaplin WF; Muntwyler J; Viles-Gonzalez JF; Weinberger J; Smith DA; Mizsei G; Badimon JJ
    J Am Coll Cardiol; 2005 Jul; 46(1):106-12. PubMed ID: 15992643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient.
    Jansen M; Gabriel H; Banyai S; Pidlich J; Weidinger F; Hörl WH; Derfler K
    Wien Klin Wochenschr; 1996; 108(14):425-31. PubMed ID: 8784984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy.
    Lima JA; Desai MY; Steen H; Warren WP; Gautam S; Lai S
    Circulation; 2004 Oct; 110(16):2336-41. PubMed ID: 15477398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of atherosclerosis.
    Arntzenius AC
    Horm Metab Res Suppl; 1988; 19():19-22. PubMed ID: 3069690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The promise of statins].
    Capurso A
    Ital Heart J Suppl; 2001 Mar; 2(3):224-9. PubMed ID: 11307780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherosclerosis. Potential targets for stabilization and regression.
    Schwartz CJ; Valente AJ; Sprague EA; Kelley JL; Cayatte AJ; Mowery J
    Circulation; 1992 Dec; 86(6 Suppl):III117-23. PubMed ID: 1424045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regression of atherosclerosis lesions].
    Weber G; Resi L; Tanganelli P
    Wien Klin Wochenschr; 1989 Oct; 101(20):698-702. PubMed ID: 2686177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
    Yonemura A; Momiyama Y; Fayad ZA; Ayaori M; Ohmori R; Higashi K; Kihara T; Sawada S; Iwamoto N; Ogura M; Taniguchi H; Kusuhara M; Nagata M; Nakamura H; Tamai S; Ohsuzu F
    J Am Coll Cardiol; 2005 Mar; 45(5):733-42. PubMed ID: 15734619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent.
    Kramsch DM; Sharma RC
    J Hum Hypertens; 1995 Mar; 9 Suppl 1():S3-9. PubMed ID: 7783112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.